Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - An international primary central nervous system lymphoma study group project

Haematologica

Volumn 98, Issue 5, 2013, Pages 808-813

  Bromberg, Jacoline E ^a   Doorduijn, Jeanette K ^a   Illerhaus, Gerald ^b   Jahnke, Kristoph ^c   Korfe, Agniezka ^c   Fischer, Lars ^c   Fritsch, Kristina ^b   Kuittinen, Outti ^d   Issa, Samar ^e   van Montfort, Cees ^a   van den Bent, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; RITUXIMAB; THIOTEPA; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; RETROSPECTIVE STUDY; RISK; SCORING SYSTEM; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TUMOR RECURRENCE; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIAL; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877078929     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.070839     Document Type: Article

References (27)

1. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER- 60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896-3902.
2. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol.1997;54(7): 854-859.
3. Bjorkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol. 2007; 18(6):1085-1089.
4. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin's lymphoma. N Engl J Med. 1995; 333(23):1540-1545.
5. Gribben JG, Goldstone AH, Linch DC, Taghipour G, Mcmillan AK, Souhami RL, et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non- Hodgkin's lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol. 1989;7(11):1621-1629.
6. Freedman AS, Takvorian T, Anderson KC, Mauch P, Rabinowe SN, Blake K, et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol. 1990;8(5):784-791.
7. Vellenga E, van Putten WL, van der Veer M, Zijlstra JM, Fibbe WE, van Oers MH, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008;111(2):537-543.
8. Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, et al. Highdose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000;6(3A):352-358.
9. Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant. 2005;11(2):93-100.
10. Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol. 1994;12(11):2415-2122.
11. van Besien K, Przepiorka D, Mehra R, Giralt S, Khouri I, Gajewski J, et al. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996;14(11):3036-3042.
12. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711-5715.
13. Hollender A, Kvaloy S, Lote K, Nome O, Holte H. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer. 2000;36(14):1762-8.
14. Paulus JA, Bos GM, Lowenberg B, van den Bent MJ. [Treatment results and the prognosis in patients with localization of non- Hodgkins-lymphoma in the central nervous system]. Ned Tijdschr Geneeskd. 1998;142(40):2196-2200.
15. Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol. 2009;88(2):133-139.
16. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114-119.
17. Gisselbrecht C, Glass B, Mounier N, Singh GD, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27): 4184-4190.
18. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26(15):2512-2518.
19. Reni M, Ferreri AJ, Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer. 1999;79:530-534.
20. Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80(2):159-65.
21. Hottinger AF, Deangelis LM, Yahalom J, Abrey LE. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007;69(11):1178-1182.
22. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111(3):1085-1093.
23. Crump M, Baetz T, Couban S, Belch A, Marellus D, Howson-Jan K, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004;101(8):1835-1842.
24. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103 (10):3684-3688.
25. Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol. 2006;85(1):45-50.
26. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178-1184.
27. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046-1052.